Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 567-574

  Landau, Susan M ^a,b   Fero, Allison ^b   Baker, Suzanne L ^b   Koeppe, Robert ^c   Mintun, Mark ^d   Chen, Kewei ^e   Reiman, Eric M ^e   Jagust, William J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

^e BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid; PET imaging

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; BIOLOGICAL MARKER; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE RATIO; WHITE MATTER; BRAIN; BRAIN MAPPING; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC USE; IMAGE PROCESSING; KINETICS; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; BRAIN; BRAIN MAPPING; CEREBELLUM; ETHYLENE GLYCOLS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; LONGITUDINAL STUDIES; MALE; NEUROIMAGING; PONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 84928257011     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.148981     Document Type: Article

References (27)

1. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890-896.
2. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
3. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972.
4. 11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:1629-1638.
5. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636-1644.
6. Fleisher AS, Chen K, Liu X, et al. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1-12.
7. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70-77.
8. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378-384.
9. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
10. Chen K, Roontiva A, Thiyyagura P, et al. Improved power to characterize longitudinal amyloid-b PET changes and evaluate amyloid-modifying treatments using a cerebral white matter reference region. J Nucl Med. 2015;56: 560-566.
11. Matthews D, Marendic B, Andrews R, et al. Longitudinal amyloid measurement for clinical trials: a new approach to overcome variability. Paper presented at: Human Amyloid Imaging; January 15-17, 2014; Miami, Florida.
12. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
13. 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39:983-989.
14. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
15. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456-1465.
16. Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N. Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. J Alzheimers Dis. 2015;43:809-821.
17. Koeppe RA. Data analysis for amyloid PET imaging: longitudinal studies. Paper presented at: Human Amyloid Imaging; January 15-17, 2014; Miami, Florida.
18. 18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450-459.
19. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-413.
20. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597-609.
21. Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol. 2012;69:623-629.
22. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310-1323.
23. Landau S, Jagust W. Florbetapir processing methods. Alzheimer's Disease Neuroimaging Initiative website. http://adni.bitbucket.org/docs/UCBERKELEYAV45/ADNI-AV45-Methods-JagustLab-04.29.14.pdf.
24. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-367.
25. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74:826-836.
26. 11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857-861.
27. Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398-1407.